ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: Secondary analysis of a randomized controlled trial

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Seegobin, Seth D ^a   Ma, Margaret H Y ^b   Dahanayake, Chanaka ^b   Cope, Andrew P ^b   Scott, David L ^c   Lewis, Cathryn M ^a   Scott, Ian C ^a,b  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; METHOTREXATE; PREDNISOLONE; ANTIRHEUMATIC AGENT; AUTOANTIBODY; AUTOANTIGEN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; CYCLOSPORIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY SCORE; DISEASE COURSE; EROSION; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SHORT FORM 36; ARTHRITIS, RHEUMATOID; BLOOD; COMBINATION DRUG THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY;

ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; CYCLOSPORINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDNISOLONE; QUALITY OF LIFE;

EID: 84892413116     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4439     Document Type: Article

References (28)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010, 376:1094-1108. 10.1016/S0140-6736(10)60826-4, 20870100.
2. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R949-R958. 10.1186/ar1767, 1257421, 16207336.
3. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012, 44:1336-1340. 10.1038/ng.2462, 3605761, 23143596.
4. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, Alfredsson L, Klareskog L. Epidemiological Investigation of Rheumatoid Arthritis study group: a genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011, 70:259-265. 10.1136/ard.2009.126821, 3015094, 21156761.
5. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Ronnelid J, Harris HE, Ulfgren A-K, Rantapaa-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38-46. 10.1002/art.21575, 16385494.
6. Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP. The protective effect of alcohol on developing rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology 2013, 52:856-867. 10.1093/rheumatology/kes376, 23287363.
7. Daha NA, Toes RE. Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease?. Nat Rev Rheumatol 2011, 7:202-203. 10.1038/nrrheum.2011.28, 21455249.
8. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M. Guideline Development Group: management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009, 338:b702. 10.1136/bmj.b702, 3266846, 19289413.
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012, 64:625-639.
10. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975. 10.1136/ard.2009.126532, 2935329, 20444750.
11. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, Scott DL. CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008, 67:656-663. CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group.
12. Ma MH, Ibrahim F, Walker D, Hassell A, Choy EH, Kiely PD, Williams R, Walsh DA, Young A, Scott DL. Remission in early rheumatoid arthritis: predicting treatment response. J Rheumatol 2012, 39:470-475. 10.3899/jrheum.110169, 22247360.
13. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350:309-318. 10.1016/S0140-6736(97)01300-7, 9251634.
14. Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, Marcolongo R, Oriente P, Pipitone V, Portioli I, Tirri G, Trotta F, Della Casa-Alberighi O. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996, 39:1006-1015. 10.1002/art.1780390618, 8651963.
15. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, Houben H, Griffiths B, Edmonds J, Bresnihan B, Boonen A, van der Linden S. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002, 46:913-920. 10.1002/art.10190, 11953967.
16. Wevers-de Boer K, Visser K, Heimans L, Ronday HK, Molenaar E, Groenendael JH, Peeters AJ, Westedt M-L, Collée G, de Sonnaville PBJ, Grillet BA, Huizinga TW, Allaart CF. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 2012, 71:1472-1477. 10.1136/annrheumdis-2011-200736, 22402145.
17. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008, 58:1293-1298. 10.1002/art.23439, 18438829.
18. van den Broek M, Dirven L, Klarenbeek NB, Molenaar TH, Han KH, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Ann Rheum Dis 2012, 71:245-248. 10.1136/annrheumdis-2011-200379, 22110122.
19. Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Mottonen T, Leirisalo-Repo M, Ilonen J, Jarvenpaa S, Luukkainen R, Hannonen P. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin Exp Rheumatol 2011, 29:500-505.
20. Canhao H, Rodrigues AM, Mourao AF, Martins F, Santos MJ, Canas-Silva J, Polido-Pereira J, Pereira Silva JA, Costa JA, Araujo D, Silva C, Santos H, Duarte C, da Silva JA, Pimentel-Santos FM, Branco JC, Karlson EW, Fonseca JE, Solomon DH. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology 2012, 51:2020-2026. 10.1093/rheumatology/kes184, 3475979, 22843791.
21. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, Thomson W, Worthington J, Emery P, Morgan AW, Wilson AG, Isaacs J, Barton A. BRAGGSS Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:69-74. Erratum in: Ann Rheum Dis 2011, 70:1519, 2596303, 18375541, BRAGGSS.
22. Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, Houvenagel E, Gaudin P, Loeuille D, Rist S, Dougados M, Sibilia J, Le Loet X, Marcelli C, Bardin T, Pane I, Baron G, Mariette X. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis'registry. Ann Rheum Dis 2012, 71:1815-1819. 10.1136/annrheumdis-2011-201109, 22615458.
23. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, Williams S, Lal P, Read SJ. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013, 72:329-336. 10.1136/annrheumdis-2011-201117, 22689315.
24. Kleinert S, Tony H-P, Krause A, Feuchtenberger M, Wassenberg S, Richter C, Rother E, Spieler W, Gnann H, Wittig BM. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study. Rheumatol Int 2012, 32:2759-2767. 10.1007/s00296-011-2033-5, 3429775, 21822659.
25. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedren S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak P-P, Crusius JB, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013, 9:e1003394. 10.1371/journal.pgen.1003394, 3610685, 23555300.
26. Kayakabe K, Kuroiwa T, Sakurai N, Ikeuchi H, Kadiombo AT, Sakairi T, Kaneko Y, Maeshima A, Hiromura K, Nojima Y. Interleukin-1 measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis. Rheumatology 2012, 51:1639-1643. 10.1093/rheumatology/kes094, 22596214.
27. Ortea I, Roschitzki B, Ovalles JG, Longo JL, de la Torre I, Gonzalez I, Gomez-Reino JJ, Gonzalez A. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. J Proteomics 2012, 77:372-382.
28. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009, 68:1094-1099. 10.1136/ard.2008.092668, 2689521, 19033290.